There are currently 1994 clinical trials in Chicago, Illinois looking for participants to engage in research studies. Trials are conducted at various facilities, including Northwestern University, Rush University Medical Center, University of Chicago and University of Chicago Comprehensive Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Durometer for Measuring Uterine Tone
NCT06284421
Recruiting
This study will evaluate the use of a durometer to measure uterine tone in parturients undergoing cesarean delivery.
Gender:
FEMALE
Ages:
Between 18 years and 50 years
Trial Updated:
05/05/2025
Locations: University of Chicago, Chicago, Illinois
Conditions: Uterine Tone Disorders, Cesarean Section Complications
Register for Updates
Response to Exercise and Nitric Oxide in PAD
NCT06657976
Recruiting
RESIST PAD is a randomized trial of 200 PAD patients to establish: 1) whether a 12-week exercise intervention significantly increases Δ nitrite at 12-week follow-up, compared to control; 2) whether exercise "responders" have greater Δ nitrite increases compared to "non-responders"; 3) among non-responders, whether supplementing exercise with nitrate-rich beetroot juice between weeks 13-24 increases Δ nitrite and improves 6-minute walk at 24-week follow-up.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
05/05/2025
Locations: Northwestern University Feinberg School of Medicine, Chicago, Illinois +1 locations
Conditions: Peripheral Artery Disease, Exercise, Intermittent Claudication, Nitric Oxide
Register for Updates
M-Vizion™ Macroscopic Radiographic Study
NCT05721859
Recruiting
Study of the patient's subsidence after revision hip arthroplasty by assessing gross stem subsidence in the femoral canal.
Gender:
ALL
Ages:
Between 21 years and 80 years
Trial Updated:
05/05/2025
Locations: Northwestern Medicine, Chicago, Illinois
Conditions: Revision Hip Arthroplasty
Register for Updates
Olaparib in Patients With HRD Malignant Mesothelioma
NCT04515836
Recruiting
In this study, researchers will give olaparib (a drug) to mesothelioma patients who have specific changes in their DNA (known as gene mutations). Researchers will give this drug to each patient on the study to find out if it will help the patient's tumor shrink or stop growing.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: University of Chicago Medical Center, Chicago, Illinois
Conditions: Mesothelioma, Homologous Recombination Deficiency
Register for Updates
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
NCT06163534
Recruiting
The study is a prospective, longitudinal, non-interventional, multicenter study of participants with HNSCC who will have tissue and blood based molecular biomarker profiling during their standard of care treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: Northwestern University Feinberg School of Medicine, Chicago, Illinois
Conditions: Head and Neck Squamous Cell Carcinoma
Register for Updates
Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
NCT05892614
Recruiting
This is a 2-Part study with Part A, a double-blind, randomized, placebo-controlled, PoC study to evaluate the efficacy, safety, and tolerability of efzofitimod in patients with SSc-ILD. The primary objective of the study is to evaluate the PoC for efficacy in a population with SSc-ILD. While improvement of ILD is the outcome of interest, the study will also evaluate changes in the skin. After initial screening (up to 4 weeks), approximately 25 eligible participants will be randomized 2:2:1 to 1... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: aTyr Investigative Site, Chicago, Illinois +2 locations
Conditions: Interstitial Lung Disease
Register for Updates
Diabetes RElated to Acute Pancreatitis and Its Mechanisms
NCT05197920
Recruiting
The overriding objective of DREAM is to conduct a prospective longitudinal (36 months) observational clinical study to investigate the incidence, etiology, and pathophysiology of diabetes mellitus (DM) following acute pancreatitis (AP).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/05/2025
Locations: Northwestern University, Chicago, Illinois +1 locations
Conditions: Acute Pancreatitis
Register for Updates
Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)
NCT04127578
Recruiting
Study J3Z-MC-OJAA is a Phase 1/2a, multicenter, open-label, ascending dose, first in-human study that will evaluate the safety of intracisternal LY3884961 administration in patients with moderate to severe Parkinson's disease with at least 1 pathogenic GBA1 mutation. Two dose level cohorts of LY3884961 are planned (Dose Level 1 and Dose Level 2). The duration of the study is 5 years. During the first year, patients will be evaluated for the effect of LY3884961 on safety, tolerability, immunogeni... Read More
Gender:
ALL
Ages:
Between 35 years and 80 years
Trial Updated:
05/05/2025
Locations: Northwestern University Feinberg School of Medicine, Dept. of Neurology, Parkinson's Disease & Movement Disorders Center, 710 N. Lake Shore Drive, 11th Floor, Chicago, Illinois
Conditions: Parkinson Disease
Register for Updates
A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis
NCT05287126
Recruiting
The purpose of this study is to determine the safety, efficacy, and pharmacokinetics (PK) of etrasimod for the treatment of moderately to severely active ulcerative colitis in adolescents (≥ 12 years up to \< 18 years of age). Participants who will complete the total 52-week treatment period will have the opportunity to continue in a Long-Term Extension (LTE) Period of up to 4 years (5 years after study enrollment).
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
05/05/2025
Locations: University of Chicago Medical Center, Chicago, Illinois
Conditions: Ulcerative Colitis
Register for Updates
Oxytocin Pharmacokinetics and Pharmacodynamics
NCT05488457
Recruiting
Oxytocin is the first-line drug to promote contraction of the uterus and prevent atony immediately after delivery. Nonetheless, unpredictable uterine atony refractory to oxytocin affects roughly 250,000 parturients annually in the U.S. and rates are increasing. This two-part study will measure the action of oxytocin at cesarean delivery. The first part will measure the pharmacokinetics of a single intravenous (IV) dose of deuterium-labeled oxytocin. The second part will measure the pharmacodynam... Read More
Gender:
FEMALE
Ages:
Between 18 years and 50 years
Trial Updated:
05/05/2025
Locations: University of Chicago, Chicago, Illinois
Conditions: Post Partum Hemorrhage, Cesarean Section Complications, Blood Loss
Register for Updates
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
NCT05519449
Recruiting
This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 in adults with metastatic castration-resistant prostate cancer (mCRPC).
Gender:
MALE
Ages:
Between 18 years and 100 years
Trial Updated:
05/05/2025
Locations: University of Chicago Medical Center, Chicago, Illinois
Conditions: Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Castration Resistant Prostatic Cancer
Register for Updates
Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy
NCT03970343
Recruiting
The OPTIMIZER Smart Post-Approval Study is a prospective, multi-center, non-randomized, single arm open label study of 620 subjects receiving an OPTIMIZER implant as standard of care. Patients to be included will have NYHA functional class III symptoms and a left ventricular ejection fraction of 25-45%
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: Advocate Illinois Masonic Medical Center, Chicago, Illinois
Conditions: Heart Failure
Register for Updates